Press


Medikamente gegen das Absterben von Haarzellen im Innenohr


Strekin AG Secures CHF 10 Million Financing for Further Development of STR001 in Sudden Hearing Loss


Strekin’s development candidate, STR001, obtains EU orphan drug designation for the treatment
of Sudden Sensorineural Hearing Loss


Strekin AG Presents Update on Phase 2 Development of STR001 and New Preclinical Data in Hearing Loss


Strekin AG announces the presentation of key STR001 data at the Conference on Molecular Biology of Hearing and Deafness, Cambridge UK


Strekin AG to develop the P38 MAPK inhibitor Pamapimod


Life Science Startup Company Strekin AG announces the launch of a Phase 2 clinical study of STR001 as a potential new treatment for hearing loss

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued.